Testosterone Enanthate Auto-Injector (Xyosted)

Quick Reference Card

Overview / What Is Xyosted?

The Basics

Xyosted is a branded form of testosterone enanthate designed specifically for subcutaneous self-injection. What makes Xyosted different from other injectable testosterone products is its delivery system: a small, prefilled autoinjector that works similarly to an EpiPen. You press it against your abdomen, activate it, and the device handles the injection automatically. There is no need to draw medication from a vial, select a needle, or perform the injection technique yourself.

For people diagnosed with hypogonadism (clinically low testosterone confirmed by blood tests and symptoms), Xyosted is one of several injectable testosterone options your provider might consider. The medication inside is testosterone enanthate, the same active compound found in Delatestryl, which has been used for testosterone replacement since 1953. The difference is in how it gets into your body: subcutaneously (under the skin) rather than intramuscularly (into the muscle), and via a spring-loaded autoinjector rather than a standard syringe.

The FDA approved Xyosted in October 2018, making it the first subcutaneous testosterone autoinjector on the market. It was developed by Antares Pharma and is available in three dose strengths (50 mg, 75 mg, and 100 mg), all in a compact 0.5 mL volume delivered through a 27-gauge needle. Clinical trials demonstrated that more than 95% of patients reported no injection-related pain, and the device's design means users never need to see the needle during the injection process.

It is important to note that Xyosted, like all testosterone products, is a Schedule III controlled substance. It requires a valid prescription. The FDA has not established safety or efficacy for treating "age-related hypogonadism" (low testosterone attributed to aging rather than a diagnosed medical condition).

The Science

Xyosted (NDA 209863) is a 505(b)(2) application referencing Delatestryl (NDA 009165, approved December 1953) as the listed drug. The product contains testosterone enanthate (17-beta-heptanoyloxy-4-androsten-3-one), CAS 315-37-7, dissolved in sesame oil and supplied in a sterile, preservative-free, single-dose autoinjector for subcutaneous administration [1][2].

The development rationale addressed several limitations of existing injectable TRT: the pain and inconvenience of intramuscular injection with large-gauge needles, the peak-trough fluctuations associated with biweekly IM dosing (200-400 mg every 2-4 weeks), and the compliance challenges of daily topical formulations. By reformulating testosterone enanthate for weekly subcutaneous delivery via a pressure-assisted autoinjector with a 27-gauge, 5/8-inch needle, the product aimed to provide a more physiologic pharmacokinetic profile with reduced injection-site discomfort [1][3].

The original NDA was submitted in December 2016, received a Complete Response in October 2017, and was resubmitted in March 2018 with resolution of identified deficiencies. FDA approval was granted in October 2018. The March 2025 label update removed the boxed warning for blood pressure increases and added updated warnings for venous thromboembolism and cardiovascular risk [1].

Medical / Chemical Identity

Generic Name: Testosterone Enanthate (Testosterone 17-beta-heptanoyloxy-4-androsten-3-one)

Brand Name:

• United States: Xyosted (Antares Pharma, Inc.)

Chemical Class: Androgen, Anabolic Steroid, Testosterone Ester (17-beta-ester derivative)

Ester Group: Heptanoate (enanthate, 7-carbon side chain at the 17-beta hydroxyl position)

• The enanthate ester increases lipophilicity, slowing absorption from the subcutaneous depot and extending duration of action
• Slightly shorter carbon chain than cypionate (7 vs 8 carbons), resulting in marginally faster ester hydrolysis

Chemical Name: (17-beta)-17-[(1-Oxoheptyl)oxy]-androst-4-en-3-one

Molecular Formula: C26H40O3

Molecular Weight: 400.59 g/mol

CAS Number: 315-37-7

Physical Properties: White to creamy white crystalline powder, stable in air. Insoluble in water, freely soluble in alcohol, chloroform, dioxane, ether, and soluble in vegetable oils.

FDA Approval: NDA 209863 (Xyosted, Antares Pharma). 505(b)(2) referencing Delatestryl (NDA 009165). Approved October 2018.

DEA Classification: Schedule III Controlled Substance under the Anabolic Steroid Control Act

Formulations Available:

• 50 mg/0.5 mL single-dose autoinjector in sesame oil (preservative-free)
• 75 mg/0.5 mL single-dose autoinjector in sesame oil (preservative-free)
• 100 mg/0.5 mL single-dose autoinjector in sesame oil (preservative-free)

NDC Numbers:

• 54436-250 (50 mg)
• 54436-275 (75 mg)
• 54436-200 (100 mg)

Referenced Listed Drug: Delatestryl (testosterone enanthate intramuscular injection, NDA 009165, approved December 1953)

Mechanism of Action / How Xyosted Works

The Basics

Testosterone does far more than most people realize. Beyond its well-known role in sexual function, it helps maintain bone density, supports muscle mass and strength, influences mood and energy levels, supports cognitive function, and plays a role in cardiovascular health and red blood cell production. When testosterone levels drop below what your body needs, the effects can show up across multiple systems.

Xyosted delivers testosterone enanthate through a tiny needle into the fat layer just under the skin of your abdomen. Once injected, the sesame oil depot sits in the subcutaneous tissue and slowly releases testosterone enanthate into your bloodstream over the following days. Your body's enzymes then clip off the enanthate ester tail, releasing free testosterone. From that point, it works just like the testosterone your body produces naturally.

Some of that testosterone gets converted to dihydrotestosterone (DHT), a more potent androgen involved in hair, skin, and prostate effects. Some gets converted to estradiol (a form of estrogen), which men also need in appropriate amounts for bone health, brain function, and cardiovascular protection. The balance between testosterone, DHT, and estradiol is part of what your provider monitors during treatment.

The weekly injection schedule is designed to keep your testosterone levels more stable than traditional biweekly intramuscular injections, which can create noticeable peaks and troughs.

The Science

Testosterone enanthate is a prodrug of testosterone. Following subcutaneous injection in sesame oil, the compound forms a depot in the subcutaneous adipose tissue from which it is slowly absorbed into the systemic circulation. Non-specific esterases in plasma and tissues hydrolyze the ester bond at the C-17 position, liberating free testosterone [1][4].

Free testosterone exerts biological effects through binding to the intracellular androgen receptor (AR), a member of the nuclear receptor superfamily. The classical genomic pathway involves ligand-AR binding, receptor dimerization, nuclear translocation, and interaction with androgen response elements (AREs) in target gene promoters, modulating transcription over hours to days. Non-genomic signaling through membrane-associated AR activates rapid second messenger cascades (MAPK/ERK, PI3K/Akt) within seconds to minutes [4].

Testosterone undergoes two primary metabolic conversions. 5-alpha reductase (types I and II) irreversibly converts testosterone to dihydrotestosterone (DHT), which has approximately 2-3 times greater AR binding affinity and mediates androgenic effects in skin, hair follicles, and prostate tissue. Aromatase (CYP19A1), expressed predominantly in adipose tissue, brain, and bone, converts testosterone to 17-beta-estradiol (E2) [4].

HPG axis suppression by exogenous testosterone is mediated through both hypothalamic (reduced GnRH pulse frequency and amplitude) and pituitary (reduced LH and FSH synthesis and secretion) mechanisms. Intratesticular testosterone concentrations, normally maintained at 40-100x serum levels, decline to near-serum levels on exogenous TRT, resulting in impaired Sertoli cell function and spermatogenic arrest [5][6].

Pathway & System Visualization

Pharmacokinetics / How Xyosted Moves Through Your Body

The Basics

When you inject Xyosted into the fat tissue of your abdomen, the medication forms a small depot under the skin. Over the next day or two, your body absorbs the testosterone enanthate from this depot into your bloodstream. Peak testosterone levels typically occur about 24-48 hours after injection, and levels gradually decline over the following days until your next weekly dose.

One of the key advantages of Xyosted's subcutaneous delivery is how stable the levels stay throughout the week. In clinical studies, the difference between the highest and lowest testosterone levels during a dosing week was much smaller with subcutaneous Xyosted than with standard intramuscular testosterone enanthate injections given every two weeks. This flatter profile means less of the "roller coaster" effect that some people experience with biweekly IM injections, where they feel great right after the shot but notice energy and mood dipping as they approach their next dose.

The three dose strengths (50, 75, and 100 mg) produce proportional increases in testosterone levels, meaning doubling the dose roughly doubles the exposure. This predictable relationship makes dose adjustments straightforward for your provider.

The Science

The pharmacokinetic profile of subcutaneous testosterone enanthate delivered via the Xyosted autoinjector was characterized in a Phase II study (n=39) and confirmed in Phase III trials (n=150 and n=133) [3][7][8].

Phase II PK Data (Week 6 Steady-State):

SC TE demonstrated dose proportionality: AUC, Cavg, Cmax, and Cmin of the 100 mg dose were approximately twice those of the 50 mg dose. Relative to 200 mg IM TE administered biweekly, the combined 100 mg SC doses demonstrated similar AUC0-inf, indicating comparable bioavailability between subcutaneous and intramuscular routes [3].

Metabolite Profiles (Week 6):

DHT and estradiol levels remained within reference ranges at both SC doses (DHT: 4-57.5 ng/dL; E2: 10-50 pg/mL). The DHT/T and E2/T ratios were similar across SC and IM groups, indicating that the route of administration does not significantly alter metabolic conversion rates [3].

Phase III Confirmation (52-Week):

The pivotal registration study confirmed long-term PK stability. Starting at 75 mg weekly with dose adjustments, 92.7% of patients achieved average total testosterone of 300-1,100 ng/dL at week 12. Mean trough concentration at week 52 was 487.2 ng/dL (SD 153.33). No patient exceeded 1,800 ng/dL at week 12 [7].

Xyosted is delivered through a pressure-assisted autoinjector with a 27-gauge, 5/8-inch needle, depositing the 0.5 mL sesame oil solution into the subcutaneous tissue of the abdomen. The 27-gauge needle is significantly smaller than the 22-25 gauge needles typically used for intramuscular testosterone injections [1][3].

Research & Clinical Evidence

The Basics

Xyosted's clinical evidence comes from a focused set of studies designed to prove that subcutaneous testosterone enanthate delivered via an autoinjector can safely and effectively restore testosterone levels in men with hypogonadism.

The key finding is straightforward: in the main clinical trial, over 92% of men achieved normal testosterone levels with weekly Xyosted injections. The vast majority experienced virtually no pain from the injections. More than 4 out of 5 men maintained their testosterone trough levels within the target range (300-650 ng/dL) over the study period.

On the safety side, the most common issues were increased hematocrit (elevated red blood cell count), elevated blood pressure, and increased PSA levels. These are known effects of testosterone therapy in general, not unique to Xyosted. About 20% of men in the 52-week trial discontinued treatment due to these adverse events.

For cardiovascular safety, the TRAVERSE trial (the largest randomized controlled trial studying TRT and heart risk) found no significant increase in major heart events with testosterone therapy versus placebo, providing important safety context for all testosterone products including Xyosted.

The Science

Pivotal Registration Study (QST-13-003)

This open-label, single-arm, 52-week Phase III trial enrolled 150 hypogonadal males who self-administered subcutaneous Xyosted 75 mg weekly, with dose adjustments to 50 or 100 mg based on week 6 trough testosterone levels [7].

Primary endpoint: 92.7% of patients achieved average total testosterone concentration of 300-1,100 ng/dL (mean 553.3, SD 127.29 ng/dL) at week 12. Cmax <1,500 ng/dL was achieved by 91.3%, and no patient exceeded 1,800 ng/dL. Mean trough at week 52: 487.2 ng/dL (SD 153.33) [7].

Phase III Safety Study (26-Week, ABPM)

A 26-week study in 133 men with symptomatic testosterone deficiency confirmed the safety and PK profile. Ambulatory blood pressure monitoring demonstrated a numerically small mean systolic BP increase of approximately 3 mmHg. All measured lipid fractions were below baseline at week 26. T trough levels ranged from 300-650 ng/dL in 82.4% of patients [8].

Phase II PK Study

The dose-finding Phase II study (n=39) established SC TE dose proportionality and demonstrated that weekly subcutaneous dosing produces more stable testosterone levels with smaller peak-trough fluctuations compared to standard biweekly 200 mg IM TE. SC bioavailability was comparable to IM, and the safety profile was benign with no serious adverse events [3].

Usability Validation

A summative usability evaluation demonstrated high injection success rates across trained and untrained users (including injection-naive patients and caregivers). The device was found to be intuitive to use with clear labeling, low potential for harm, and high success rates regardless of prior injection experience [9].

TRAVERSE Trial (Class-Level Cardiovascular Evidence)

The TRAVERSE trial (n=5,246) demonstrated non-inferiority of testosterone gel vs placebo for the primary composite endpoint of MACE (cardiovascular death, nonfatal MI, nonfatal stroke) with a hazard ratio of 0.96 (95% CI: 0.78-1.17) over a mean follow-up of 33 months in men aged 45-80 with cardiovascular risk factors. While TRAVERSE studied transdermal testosterone rather than subcutaneous Xyosted, the cardiovascular safety data provides important class-level context [10].

Evidence & Effectiveness Matrix

Benefits & Therapeutic Effects

The Basics

The primary benefit of Xyosted is that it restores testosterone to normal physiological levels in men with hypogonadism. The therapeutic effects are those of testosterone replacement therapy broadly, delivered through a uniquely convenient system.

Many men on TRT report improvements in energy, libido, mood, body composition, and overall quality of life. These benefits are well-documented across multiple clinical trials and represent the core reason testosterone replacement exists as a treatment. With Xyosted specifically, the weekly subcutaneous injection produces more stable testosterone levels than traditional biweekly intramuscular shots, which may contribute to steadier energy and mood throughout the week.

Beyond the hormonal benefits, Xyosted offers practical advantages that matter to many users. The autoinjector eliminates the need to draw medication from a vial, select and attach a needle, or perform manual injection technique. For people with needle anxiety, limited dexterity, or conditions like Parkinson's disease that make self-injection difficult, this can be the difference between adhering to treatment and abandoning it.

The preservative-free sesame oil formulation may also benefit users who have experienced injection site reactions or irritation with other testosterone products containing preservatives like benzyl alcohol.

The Science

The therapeutic effects of testosterone replacement at physiological levels are well-established through landmark trials and meta-analyses, applicable to Xyosted as a delivery vehicle for testosterone enanthate [4][10][11]:

• Sexual function: The TTrials demonstrated improvement in sexual desire (P<0.001), erectile function, and sexual activity in hypogonadal men aged 65+ over 12 months of testosterone therapy [11]
• Body composition: Meta-analyses consistently demonstrate increased lean mass (+1.6 kg) and decreased fat mass (-2.0 kg) with TRT in hypogonadal men [4]
• Bone density: TTrials bone trial showed significant improvement in volumetric BMD of spine and hip over 12 months [11]
• Mood and vitality: Moderate improvements in depressive symptoms and vitality reported in TTrials, with more pronounced effects in men with more severe baseline symptoms [11]
• Energy and physical function: Improved walking distance demonstrated in the TTrials physical function trial [11]

Xyosted-specific benefits relate primarily to its pharmacokinetic profile and delivery system. The weekly SC dosing regimen achieves a Cavg within the normal range (300-1,100 ng/dL) with significantly lower peak-trough fluctuation than biweekly IM dosing (Cavg range 257-673 ng/dL for 50 mg SC vs 681-3,758 ng/dL for 200 mg IM) [3].

Risks, Side Effects & Safety

The Basics

Like all testosterone products, Xyosted carries real risks that require monitoring. The most important thing to understand is that these risks are manageable with proper medical supervision, but they are not trivial and deserve honest discussion.

Common side effects that may occur include acne, oily skin, injection site bruising or redness, fluid retention, and mood changes. Most of these are mild and either resolve over time or respond to dose adjustment.

Elevated red blood cell count (polycythemia) is the most frequently reported issue with Xyosted and the leading reason men stopped treatment in the pivotal clinical trial. When your hematocrit rises above 54%, the risk of blood clots increases. Your provider will monitor this with blood tests, starting before treatment and periodically during it. If your hematocrit gets too high, your options include reducing the dose, temporarily stopping treatment, or therapeutic phlebotomy (blood donation or removal).

Blood pressure may increase modestly. The 52-week Xyosted trial showed a mean increase of about 3 mmHg in systolic blood pressure. The original FDA label included a boxed warning about blood pressure increases, but this was removed in the March 2025 label update based on subsequent data review.

Heart health has been a topic of considerable discussion in the TRT field. The TRAVERSE trial, the largest randomized controlled trial designed to study cardiovascular safety of TRT, found no significant increase in major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) with testosterone therapy compared to placebo. The hazard ratio was 0.96 (95% CI: 0.78-1.17) over 33 months of follow-up in men aged 45-80 who already had cardiovascular risk factors or established heart disease. However, TRAVERSE did note increased rates of atrial fibrillation, pulmonary embolism, and acute kidney injury in the testosterone group, which warrants continued monitoring [10].

Prostate effects require monitoring. PSA levels may increase during testosterone therapy. Current evidence does not support a causal link between TRT at physiological levels and prostate cancer initiation (the "saturation model" suggests that the androgen receptor is saturated at normal testosterone levels). However, prostate monitoring remains standard practice [4].

The Science

Clinical Trial Safety Data (52-Week Pivotal Study, n=150):

Most frequently reported TEAEs (incidence >= 2%): increased hematocrit, hypertension, increased PSA, injection site bruising, injection site erythema, increased estradiol. Treatment-emergent adverse events led to discontinuation in 30 of 150 men (20%), most commonly due to increased hematocrit, hypertension, and increased PSA [7].

Phase II Safety (n=39):

No deaths or serious TEAEs. No cardiovascular events. 33.3% had at least one TEAE, all mild to moderate. Only 4 drug-related TEAEs (2 insomnia, 1 acne, 1 injection site ecchymosis). No discontinuations due to TEAEs. 97.4% completion rate [3].

Polycythemia/Erythrocytosis:

Hematocrit monitoring is mandatory. The threshold for intervention is >54%. Testosterone stimulates erythropoietin production and erythropoiesis. Subcutaneous administration may produce lower hematocrit elevation than intramuscular dosing based on general route-comparison data, possibly due to more stable testosterone levels without supraphysiologic peaks [1][7].

Cardiovascular Risk:

The TRAVERSE trial (n=5,246, testosterone gel vs placebo, mean follow-up 33 months) demonstrated non-inferiority for the composite MACE endpoint (HR 0.96, 95% CI: 0.78-1.17) in men aged 45-80 with preexisting or high risk for cardiovascular disease. The upper bound of the 95% CI (1.17) was below the prespecified non-inferiority margin of 1.20. TRAVERSE also identified increased incidence of atrial fibrillation, pulmonary embolism, and acute kidney injury with testosterone therapy [10].

Contraindications:

• Men with breast carcinoma or known/suspected prostate carcinoma
• Women who are pregnant (testosterone is teratogenic)
• Active polycythemia (hematocrit >54% at baseline)
• Desire for near-term fertility (exogenous testosterone suppresses spermatogenesis)

March 2025 Label Update:

• Boxed Warning for Blood Pressure Increases: REMOVED
• Updated: Venous thromboembolism warning (Section Section 4.2)
• Updated: Cardiovascular risk warning (Section Section 4.4)

Understanding your personal risk profile isn't a one-time calculation — it evolves as your treatment progresses. Doserly helps you see the bigger picture by analyzing side effect patterns over time, showing whether issues are resolving, persisting, or emerging as your body adjusts to testosterone therapy.

The app's analytics can reveal connections between side effects and specific aspects of your protocol — like whether hematocrit creep correlates with a recent dose increase, or whether splitting your weekly dose into two injections reduced estrogen-related symptoms. This kind of insight helps you and your provider make informed adjustments based on your actual experience, not just population-level averages.

Dosing & Treatment Protocols

The Basics

Xyosted's dosing is more straightforward than most injectable testosterone products. Your provider will typically start you at 75 mg once a week, injected subcutaneously in the abdominal area. After six weeks, you will have a blood draw to check your trough testosterone level (taken seven days after your most recent injection, right before the next one is due).

Based on that result, your dose may be adjusted:

• If your trough is 650 ng/dL or higher, the dose decreases to 50 mg
• If your trough is below 350 ng/dL, the dose increases to 100 mg
• If your trough is between 350 and 650 ng/dL, you stay at 75 mg

The maximum approved dose is 100 mg once weekly. This simple titration algorithm is one of the advantages of Xyosted's fixed-dose autoinjector system.

A limitation worth noting: because each autoinjector delivers a fixed dose (50, 75, or 100 mg), there is no ability to make fine adjustments between these increments. If your optimal dose would be 60 mg or 85 mg, Xyosted cannot accommodate that. Some providers and patients view this as a drawback compared to drawing from a vial, where any dose can be measured.

The Science

The dose-adjustment algorithm is based on Phase III data demonstrating that a trough concentration between 350 and 650 ng/dL (measured at 168 hours post-dose) generally provides average testosterone exposures within the normal range (300-1,100 ng/dL) during the dosing interval [1][7].

Starting dose of 75 mg SC weekly achieves mean steady-state Cavg of approximately 550 ng/dL based on interpolation between 50 mg (Cavg 422.4 ng/dL) and 100 mg (Cavg 895.5 ng/dL) Phase II data. Dose proportionality allows predictable adjustment [3].

The fixed-dose autoinjector format (50, 75, 100 mg) limits protocol customization. Unlike vial-and-syringe systems, intermediate doses or split dosing (e.g., 37.5 mg twice weekly) cannot be precisely achieved. One Drugs.com reviewer reported using "50 mg 3x a week" for more stable levels, but this off-label protocol uses 3 autoinjectors per week [1].

Dosing protocols often change over the course of treatment — starting doses get adjusted, injection frequencies get split, esters get switched. Doserly maintains a complete history of every protocol change, giving you and your provider a clear picture of what's been tried and how each adjustment affected your symptoms and lab values.

The app's adherence analytics show your consistency patterns and can highlight whether missed doses or timing variations correlate with symptom changes. When your provider is considering a dose adjustment based on your trough levels, having this data available makes the conversation more productive and the decision more informed.

What to Expect (Timeline)

Days 1-7: You may notice a subtle energy lift, though some of this can be psychological. Injection site may show mild bruising or redness. With the autoinjector, most users report feeling nothing during injection.

Weeks 2-4: Libido changes are often the first noticeable effect. Energy improvements may become apparent. Your provider will not typically adjust your dose yet; the body needs time to reach steady-state.

Week 6: First trough level blood draw. Your provider will assess whether dose adjustment is needed. By this point, you should have a sense of whether energy and mood are improving.

Months 1-3: Sexual function improvements typically become more consistent. Initial body composition changes may begin. Hematocrit starts rising and will be monitored. Mood stabilization is common in this window.

Months 3-6: Body composition changes become more apparent (reduced fat, increased lean mass). Strength improvements if exercising regularly. Bone density changes beginning (not perceptible). First comprehensive lab panel reassessment typically occurs.

Months 6-12: Full sexual function benefits realized. Significant body composition changes. Bone density measurably improved per DEXA if baseline osteopenia was present. Annual review with provider recommended.

Ongoing maintenance: Annual review including symptom reassessment, continued hematocrit monitoring (threshold >54%), PSA per age-appropriate guidelines, lipid panel, and dose reassessment.

Individual response varies widely. Not all symptoms resolve with testosterone replacement alone, and some benefits take months to fully manifest. Dose adjustment is common and expected during the first 3-6 months.

Fertility Preservation & HPG Axis

Exogenous testosterone, regardless of the delivery method, suppresses the hypothalamic-pituitary-gonadal (HPG) axis. Xyosted is no exception. When you inject testosterone from an external source, your brain detects adequate circulating levels and reduces the signals (GnRH, LH, FSH) that tell your testes to produce testosterone and sperm.

Impact on spermatogenesis: Approximately 40-60% of men on TRT achieve azoospermia (zero sperm count) by 6 months, with the remainder typically showing severe oligospermia (<1 million/mL). This effect is usually reversible after discontinuation, but recovery is variable (6-24+ months) and not guaranteed [5][6].

Fertility counseling is essential before starting Xyosted or any testosterone product. If you are a man of reproductive age who may want biological children in the future, discuss this with your provider before initiating treatment.

Options for fertility preservation:

• Sperm banking before TRT initiation is the most reliable safeguard
• HCG co-administration (250-500 IU 2-3 times weekly) may maintain intratesticular testosterone and spermatogenesis during TRT, though evidence is not definitive and this is off-label
• Clomiphene or enclomiphene as alternatives to exogenous testosterone: SERMs can raise endogenous testosterone by stimulating LH/FSH without suppressing spermatogenesis, but are off-label for this use
• Gonadorelin (GnRH analog) is sometimes used in place of HCG for similar purposes

Recovery after discontinuation depends on multiple factors: duration of TRT use (longer use = slower recovery), age, pre-TRT hormonal status, whether HCG was used concurrently, and individual variability. Men with primary hypogonadism (testicular failure) have limited recovery potential regardless, while those with secondary hypogonadism (pituitary/hypothalamic dysfunction) generally have a better prognosis [5][6].

This is not a minor side effect. The Xyosted prescribing information specifically notes that "infertility has been observed in men receiving testosterone replacement therapy" [1].

Interactions & Compatibility

Drug-Drug Interactions:

• Anticoagulants (warfarin, DOACs): Testosterone may enhance anticoagulant effect. More frequent INR monitoring recommended, especially at initiation and termination of TRT [1]
• Insulin and diabetes medications: Testosterone may improve insulin sensitivity, potentially requiring dose reduction of diabetes medications [1]
• Corticosteroids: Concurrent use may result in increased fluid retention. Use caution, especially in patients with hepatic or cardiac disease [1]
• 5-alpha reductase inhibitors (finasteride, dutasteride): Block conversion of testosterone to DHT, affecting androgenic side effect profile and potentially modifying some therapeutic effects
• Aromatase inhibitors (anastrozole): May be co-prescribed if estradiol levels cause symptomatic gynecomastia, though routine use is not recommended by guidelines

Supplement Interactions:

• DHEA: Additive androgenic effects; generally not recommended concurrently with TRT
• Boron: May increase free testosterone by reducing SHBG
• Zinc: Supports testosterone production; supplementation may be synergistic in zinc-deficient individuals
• Saw palmetto: 5-alpha reductase inhibition; may modify DHT-mediated effects

Lifestyle Factors:

• Alcohol: Suppresses testosterone production and increases aromatization; moderation recommended
• Sleep: Critical for testosterone production and recovery; TRT may worsen obstructive sleep apnea in susceptible individuals
• Exercise: Resistance training is synergistic with TRT for body composition and strength outcomes
• Body composition: Weight loss alone may normalize testosterone in obese men, potentially reducing or eliminating the need for TRT

Cross-links to related guides:

• Testosterone Enanthate (Delatestryl) (same active compound, IM route)
• Testosterone Cypionate (Depo-Testosterone) (closely related ester, IM route)
• Anastrozole (Arimidex) (AI for estrogen management)
• HCG (fertility preservation during TRT)
• Enclomiphene (alternative to exogenous testosterone)

Decision-Making Framework

Deciding whether Xyosted is the right TRT formulation involves two separate questions: first, whether you are a candidate for testosterone replacement therapy at all, and second, whether the subcutaneous autoinjector delivery system is the best option for you.

Diagnosis first: The Endocrine Society requires two morning total testosterone measurements below the lower limit of normal (typically <264-300 ng/dL, depending on the laboratory) plus symptoms of hypogonadism. The AUA uses a 300 ng/dL threshold. These criteria must be met before TRT is appropriate [12].

When Xyosted may be a good fit:

• You have a confirmed diagnosis of hypogonadism
• You prefer subcutaneous injection over intramuscular injection
• You have needle anxiety or difficulty with self-injection technique
• You want a pre-measured dose that eliminates preparation steps
• You value the convenience of a compact, ready-to-use device
• Your insurance covers it, or you are willing to pay the cost premium

When Xyosted may not be the best choice:

• You need a dose between the available increments (50, 75, 100 mg)
• You prefer more frequent dosing (EOD or daily micro-dosing)
• Cost is a primary concern and insurance coverage is unavailable
• You are comfortable with vial-and-syringe injection technique

Questions to ask your provider:

• "Is my diagnosis based on two morning testosterone measurements plus symptoms?"
• "Are there reversible causes of my low testosterone that should be addressed first?" (obesity, sleep apnea, opioid use, pituitary pathology)
• "What are the differences between Xyosted and other testosterone formulations for my situation?"
• "How will we monitor for side effects, and what is the plan if my hematocrit rises?"
• "What are my options for fertility preservation?"

Administration & Practical Guide

Xyosted autoinjector technique:

1. Prepare: Gather one XYOSTED autoinjector, one alcohol swab, and one cotton ball or gauze. Allow the autoinjector to reach room temperature if stored in a cool location. Visually inspect the solution; it should be colorless or slightly yellow. Do not use if cloudy or if particles are visible.
2. Select site: Choose an injection site on the abdomen. Avoid the area within 2 inches of the navel. Rotate sites with each injection. Clean the site with an alcohol swab and let it dry.
3. Inject: Remove the autoinjector cap. Place the device firmly against the cleaned skin at a 90-degree angle. Press down until you hear the first click (this indicates the needle has been inserted and injection has started). Continue holding firmly for approximately 10 seconds until you hear the second click (injection complete). An orange indicator will be visible in the viewing window, confirming dose delivery.
4. Post-injection: Remove the autoinjector and apply gentle pressure with a cotton ball or gauze. Do not massage the injection site. A small amount of bleeding or bruising is normal. Dispose of the used autoinjector in a sharps container.

Important administration notes:

• XYOSTED is for subcutaneous injection in the abdominal region only. Do not inject intramuscularly or intravascularly [1]
• Do not refrigerate or freeze. Store at room temperature (20-25 degrees C / 68-77 degrees F) [1]
• Each autoinjector is single-use. Do not attempt to reuse or save unused portions
• The 27-gauge, 5/8-inch needle is pre-attached and hidden during use. You never need to see the needle
• Most users report the injection is virtually painless; more than 95% of clinical trial participants reported no injection-related pain [7]

Tips from the community:

• Pinch the injection area firmly before and during injection to reduce sensation
• Hold the device against the skin for a full 10 seconds after the second click to ensure complete delivery
• Some users report needing significant pressure to activate the autoinjector spring; this is by design, not a malfunction

Getting the administration routine right can take some experimenting. Doserly tracks not just whether you took your dose, but when, where you injected, and how — building a picture of your actual routine that can reveal opportunities for optimization.

The app's analytics can show whether small timing shifts affect how you feel, whether your injection site rotation is balanced, and how your adherence has evolved since you started treatment. When your provider asks about compliance, you'll have real data — not an estimate — and when something feels off, you can check whether an administration change might be the reason.

Monitoring & Lab Work

Pre-TRT baseline labs:

• Total testosterone (two morning draws, confirming <300 ng/dL)
• Free testosterone (calculated or equilibrium dialysis)
• LH, FSH (to distinguish primary vs secondary hypogonadism)
• Estradiol
• SHBG
• Prolactin (if secondary hypogonadism suspected)
• CBC with hematocrit
• PSA (age-appropriate)
• Lipid panel
• Comprehensive metabolic panel
• DEXA if osteoporosis risk is present

Initial follow-up with Xyosted:

• Week 6: Trough total testosterone (measured 7 days after most recent dose). This determines whether dose adjustment is needed (decrease to 50 mg if trough >= 650 ng/dL, increase to 100 mg if trough < 350 ng/dL)
• Week 12: Repeat trough level after 6 weeks of adjusted dose (if dose was changed). Also check hematocrit.
• Check for side effects: injection site reactions, mood changes, sleep quality

Ongoing monitoring schedule:

• Hematocrit: Every 3-6 months initially, then every 6-12 months. Threshold >54% requires intervention (dose reduction, route change, or therapeutic phlebotomy)
• PSA: Per age-appropriate screening guidelines, annually for men >40
• Testosterone levels: Trough level periodically while on treatment
• Estradiol: Only if symptomatic (gynecomastia, significant fluid retention, mood effects); not routine per guidelines
• Lipid panel: Annually
• Bone density (DEXA): If osteoporosis was an indication for treatment
• Semen analysis: If fertility is a concern

Annual review checklist: Symptom reassessment, continued indication, risk-benefit discussion, dose optimization consideration, hematocrit check, PSA (if indicated), lipid panel.

Estrogen Management on TRT

Testosterone converts to estradiol via the aromatase enzyme, primarily in adipose tissue. This is a normal and necessary physiological process. Estradiol is important for bone health, cardiovascular health, libido, and cognitive function in men.

Xyosted PK data shows estradiol levels within normal range: In the Phase II study, mean estradiol at 50 mg SC was 25.6 pg/mL and at 100 mg SC was 48.3 pg/mL, both within the reference range (10-50 pg/mL). The E2/T ratio was similar between SC and IM routes [3].

When estrogen management matters: Only when clinical symptoms or clearly elevated E2 levels are present. Routine aromatase inhibitor use is NOT recommended by Endocrine Society or AUA guidelines [12].

The community vs clinical perspective: Online men's health communities place heavy emphasis on E2 management, often targeting specific numerical ranges (commonly 20-35 pg/mL). Clinical guidelines do not specify a target E2 range for men on TRT and recommend treating symptoms rather than chasing numbers. Excessive E2 suppression causes joint pain, mood disturbance, decreased libido, and bone density loss [12].

High E2 symptoms: Gynecomastia, excessive fluid retention, emotional lability, nipple sensitivity
Low E2 symptoms: Joint pain/stiffness, low libido (paradoxically), dry skin, fatigue, depression, bone density loss

The subcutaneous route may produce slightly different aromatization patterns than intramuscular injection due to the depot forming in adipose tissue (where aromatase is concentrated), but the Phase II data suggests that metabolite ratios are comparable between routes [3].

Stopping TRT / Post-Cycle Considerations

HPG axis recovery: When exogenous testosterone is discontinued, LH and FSH remain suppressed for weeks to months. Endogenous testosterone production may take 6-24+ months to recover, and recovery to pre-TRT levels is not guaranteed.

Is Xyosted-specific TRT lifelong? For men with primary hypogonadism (testicular failure), testosterone replacement is typically lifelong regardless of formulation. For secondary hypogonadism, addressing underlying causes (weight loss, sleep apnea treatment, opioid cessation) may restore endogenous production. For age-related decline, the answer is individualized.

PCT protocols (adapted from community practice, not standardized in clinical guidelines for TRT discontinuation):

• HCG taper: 1000-2000 IU every other day for 2-4 weeks, then taper
• Clomiphene citrate: 25-50mg daily for 4-8 weeks to stimulate LH/FSH recovery
• Enclomiphene: Newer SERM, may have fewer side effects than clomiphene

Factors affecting recovery: Duration of TRT use, age, pre-TRT hormonal status, concurrent HCG use during TRT, genetic factors. Primary hypogonadism has limited recovery prognosis; secondary hypogonadism has better prognosis.

Symptom management during recovery: Expect symptom return (fatigue, low libido, mood changes). SERMs can help bridge the gap. Exercise, sleep optimization, and stress management are supportive measures.

Special Populations & Situations

Obese Men

Weight loss alone may normalize testosterone. Consider lifestyle intervention before initiating TRT. If Xyosted is prescribed, higher aromatization may occur due to increased adipose tissue. The subcutaneous abdominal injection site is accessible regardless of body habitus.

Men with Sleep Apnea

TRT may exacerbate obstructive sleep apnea. CPAP optimization recommended before and during TRT. Xyosted's stable weekly levels (vs biweekly IM peaks) may theoretically reduce sleep apnea exacerbation risk, though this has not been specifically studied.

Men with Prostate Cancer History

Evolving evidence; the saturation model suggests exogenous T at physiological levels may not further stimulate the prostate. Remains controversial; requires specialized urological consultation. Xyosted is contraindicated in men with known or suspected prostate carcinoma [1].

Cardiovascular Disease History

TRAVERSE trial provides reassurance for non-inferiority. Subcutaneous route avoids supraphysiologic peaks associated with large-dose IM injections. Hematocrit monitoring is critical.

Type 2 Diabetes

TRT may improve insulin sensitivity, HbA1c, and metabolic parameters in hypogonadal diabetic men. May require diabetes medication dose adjustment. Xyosted prescribing information notes potential for decreased blood glucose and insulin requirements [1].

Adolescents and Young Men

Safety and efficacy of Xyosted have not been established in males under 18 years of age [1]. Allometric scaling models suggest potential utility for adolescent hypogonadism, but further study is needed [13].

Transgender Men (FTM)

Xyosted is used by transgender men for masculinizing hormone therapy. Community reports from FTM users are highly positive regarding the autoinjector format, particularly for users with needle anxiety. Dosing goals, monitoring, and fertility counseling differ from classical hypogonadism treatment.

Older Men (>65)

Age-related decline vs true hypogonadism distinction is important. TRAVERSE and TTrials data primarily from this population. Xyosted's lower peak levels compared to IM may reduce polycythemia risk in older men.

Regulatory, Insurance & International

United States (FDA/DEA):

• NDA 209863, approved October 2018
• Schedule III controlled substance
• FDA-approved for primary and hypogonadotropic hypogonadism only; NOT approved for "age-related hypogonadism"
• March 2025 label update: removed boxed BP warning, updated VTE and CV risk warnings
• Manufactured by Antares Pharma, Inc. (Ewing, NJ)

Cost and insurance:

• Xyosted is significantly more expensive than generic testosterone enanthate or cypionate vials
• Approximate retail cost: $655 per month (4 autoinjectors) without insurance
• With insurance and manufacturer coupons: $0-$100 per month (highly variable)
• Generic testosterone cypionate 200 mg/mL vial: approximately $34 per 10 mL
• Insurance coverage varies widely; prior authorization is commonly required
• Some providers have successfully advocated for insurance coverage based on medical necessity (needle phobia, dexterity limitations, dosing accuracy concerns)

International availability:

• Xyosted is currently a US-only product
• Not available in the UK, Canada, Australia, or EU markets
• International travelers using Xyosted should carry documentation (prescription, DEA Schedule III requirements apply)

Generic testosterone enanthate alternatives:

• Delatestryl (testosterone enanthate, intramuscular) is available as a generic
• Compounded testosterone enanthate available through 503A and 503B pharmacies

Frequently Asked Questions

Q: What is Xyosted and how is it different from regular testosterone injections?
A: Xyosted is a prefilled autoinjector that delivers testosterone enanthate subcutaneously (under the skin) in the abdominal area. It uses a small 27-gauge needle and works like an EpiPen. The main differences from standard injections are the subcutaneous route (vs intramuscular), the autoinjector format (vs manual syringe), the weekly fixed-dose schedule, and the preservative-free sesame oil formulation.

Q: Is Xyosted the same medication as Delatestryl?
A: Both contain testosterone enanthate as the active ingredient. The key differences are the delivery system (autoinjector vs vial and syringe), the route (subcutaneous vs intramuscular), and the dosing (50-100 mg weekly vs 200-400 mg every 2-4 weeks). Xyosted uses sesame oil and is preservative-free; Delatestryl contains chlorobutanol as preservative.

Q: Does the Xyosted injection hurt?
A: In clinical trials, more than 95% of patients reported no injection-related pain. The 27-gauge needle is much smaller than the 22-25 gauge needles typically used for intramuscular testosterone injections. Many community users report that the injection is virtually painless, with some describing not being sure the injection actually happened.

Q: Why is Xyosted so expensive compared to generic testosterone?
A: Xyosted is a branded combination drug-device product. Its cost reflects the autoinjector device, the preservative-free formulation, and the brand pricing. Generic testosterone enanthate or cypionate from a vial costs a fraction of the price. Whether the convenience premium is worthwhile depends on individual circumstances, insurance coverage, and personal preferences.

Q: Can I use Xyosted more than once a week?
A: The FDA-approved dosing is once weekly. Some users report using lower-dose autoinjectors more frequently (e.g., 50 mg every other day or three times weekly), but this is off-label, significantly increases cost, and has not been studied for safety or efficacy.

Q: Will Xyosted affect my fertility?
A: Yes. Like all exogenous testosterone products, Xyosted suppresses the HPG axis and can significantly reduce sperm production, potentially to zero. If you may want biological children in the future, discuss fertility preservation options with your healthcare provider before starting treatment.

Q: Can I switch from testosterone cypionate to Xyosted?
A: Yes, with your provider's guidance. Testosterone enanthate and cypionate are very similar esters with nearly identical clinical profiles. Your provider may need to adjust the dose and will likely check trough levels after the switch to confirm appropriate dosing.

Q: Is Xyosted covered by insurance?
A: Coverage varies widely. Some plans cover Xyosted with prior authorization; others do not. Co-pays range from $0 to $100+ per month when covered. Antares Pharma offers copay assistance programs. Without insurance, the retail cost is approximately $655 per month. Discuss coverage with your provider and insurance company.

Q: Can I travel with Xyosted?
A: Yes, but plan ahead. Carry your prescription documentation. Testosterone is a Schedule III controlled substance and may have restricted status in other countries. Keep Xyosted at room temperature (do not refrigerate or freeze). TSA allows injectable medications through security with proper documentation.

Q: Why was the blood pressure boxed warning removed from Xyosted's label?
A: The March 2025 label update removed the boxed warning for blood pressure increases based on FDA review of subsequent data. A warning about blood pressure increases and cardiovascular risk remains in the prescribing information, but it was determined that a boxed warning (the most serious type of FDA warning) was no longer warranted.

Myth vs. Fact

Myth: Xyosted is a completely different medication from other testosterone injections.
Fact: Xyosted contains the same active compound (testosterone enanthate) that has been used in injectable TRT since 1953. The innovation is in the delivery system (subcutaneous autoinjector) and formulation (preservative-free sesame oil), not in the testosterone itself. Clinical outcomes at equivalent doses are expected to be similar to those of standard testosterone enanthate.

Myth: TRT causes heart attacks.
Fact: The TRAVERSE trial (n=5,246), the largest RCT designed to assess cardiovascular safety of TRT, found no significant increase in major adverse cardiovascular events with testosterone therapy versus placebo (HR 0.96, 95% CI: 0.78-1.17) over 33 months in a population of men aged 45-80 with cardiovascular risk factors. Earlier observational studies that raised cardiovascular concerns had significant methodological limitations. However, TRAVERSE did note increased rates of atrial fibrillation, pulmonary embolism, and acute kidney injury, warranting continued monitoring [10].

Myth: TRT causes prostate cancer.
Fact: Current evidence does not support a causal link between TRT at physiological replacement levels and prostate cancer initiation. The androgen saturation model suggests that the androgen receptor is maximally stimulated at relatively low testosterone concentrations, and increasing testosterone to normal physiological levels does not further stimulate prostate growth. However, TRT is contraindicated in men with known or suspected prostate cancer, and PSA monitoring remains standard practice [4].

Myth: Subcutaneous testosterone doesn't work as well as intramuscular.
Fact: Phase II data for Xyosted demonstrated that subcutaneous and intramuscular bioavailability of testosterone enanthate are comparable (similar AUC0-inf). The subcutaneous route actually produces more stable testosterone levels with smaller peak-trough fluctuations than standard biweekly IM dosing [3].

Myth: Once you start TRT, you can never stop.
Fact: This is nuanced. Men with primary hypogonadism (testicular failure) typically need lifelong replacement because the underlying cause is permanent. Men with secondary hypogonadism who address underlying causes (weight loss, treating sleep apnea, stopping medications that suppress testosterone) may be able to discontinue TRT. HPG axis recovery after TRT discontinuation is possible but variable (6-24+ months), and recovery to pre-TRT levels is not guaranteed [5][6].

Myth: TRT will permanently destroy your fertility.
Fact: TRT does suppress spermatogenesis, and approximately 40-60% of men on TRT achieve azoospermia by 6 months. However, spermatogenesis typically recovers after discontinuation, though the timeline is variable (6-24+ months) and full recovery is not guaranteed. Sperm banking before starting TRT is recommended for men who may want biological children. HCG co-administration during TRT may help preserve fertility [5][6].

Myth: Higher testosterone doses are always better.
Fact: Therapeutic replacement aims to restore testosterone to the normal physiological range (300-1,100 ng/dL for total testosterone). Supraphysiological levels (above the normal range) carry increased risk of polycythemia, cardiovascular events, and other side effects without proportionally greater therapeutic benefit. Xyosted's maximum dose of 100 mg weekly is designed to maintain levels within the therapeutic range.

Myth: TRT clinics are all the same quality.
Fact: There is significant variance in TRT clinic quality. Red flags include providers who prescribe testosterone without confirming the diagnosis with two morning testosterone measurements, who do not discuss risks and alternatives, who do not monitor hematocrit and PSA, or who routinely prescribe aromatase inhibitors to all patients. Endocrinologists, urologists with andrology interest, and men's health specialists with proper diagnostic protocols provide the most evidence-based care.

Myth: Xyosted is just a way for a drug company to charge more for the same medication.
Fact: While Xyosted does cost significantly more than generic testosterone enanthate vials, the autoinjector format provides genuine clinical benefits for certain populations: patients with needle phobia, limited dexterity, or conditions affecting self-injection ability. The preservative-free formulation may benefit patients who react to preservatives in other formulations. The fixed-dose format eliminates dosing errors. Whether the convenience premium is justified depends on individual circumstances.

Sources & References

Clinical Guidelines

[1] Antares Pharma, Inc. XYOSTED (testosterone enanthate) injection, for subcutaneous use. Full Prescribing Information. DailyMed, NLM/NIH. March 2025 label. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a3d204c-be26-49e0-8599-0ac12a272e81

[12] Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744.

Landmark Trials

[10] Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389(2):107-117. (TRAVERSE Trial)

[11] Snyder PJ, Bhasin S, Cunningham GR, et al. Lessons From the Testosterone Trials. Endocr Rev. 2018;39(3):369-386. (TTrials)

Clinical Studies (Xyosted-Specific)

[3] Kaminetsky J, Jaffe JS, Swerdloff RS. Pharmacokinetic profile of subcutaneous testosterone enanthate delivered via a novel, prefilled single-use autoinjector: A phase II study. Sex Med. 2015;3(4):263-273. PMID: 26797061.

[7] Kaminetsky JC, McCullough A, Hwang K, Jaffe JS, Wang C. A 52-Week Study of Dose Adjusted Subcutaneous Testosterone Enanthate in Oil Self-Administered via Disposable Auto-Injector. J Urol. 2019;201(3):587-594. PMID: 30296416.

[8] Gittelman M, Jaffe JS, Kaminetsky JC. Safety of a New Subcutaneous Testosterone Enanthate Auto-Injector: Results of a 26-Week Study. J Sex Med. 2020;17(2):1741-1748. PMID: 31551193.

[9] Arora S, Moclair B, Murphy K, et al. Summative Usability Evaluation of the SCTE-AI Device: A Novel Prefilled Autoinjector for Subcutaneous Testosterone Administration. J Sex Med. 2018;15(12):1707-1715. PMID: 30393104.

FDA Regulatory Documents

[2] FDA Summary Review. NDA 209863 (Xyosted). Cross-Discipline Team Leader Memo. Approved October 2018. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209863Orig1s000SumR.pdf

General References

[4] Surampudi PN, Wang C, Swerdloff R. Hypogonadism in the aging male diagnosis, potential benefits, and risks of testosterone replacement therapy. Int J Endocrinol. 2012;2012:1-20.

[5] Wu FC, Farley TM, Peregoudov A, Waites GM. Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. World Health Organization Task Force on Methods for the Regulation of Male Fertility. Fertil Steril. 1996;65(3):626-636.

[6] Liu PY, Swerdloff RS, Christenson PD, et al. Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis. Lancet. 2006;367(9520):1412-1420.

Adolescent PK Research

[13] Vogiatzi MG, Jaffe JS, Amy T, Rogol AD. Allometric scaling of testosterone enanthate pharmacokinetics to adolescent hypogonadal males (IM and SC administration). J Endocr Soc. 2023;7(6):bvad059. PMID: 37180212.

Related Guides & Cross-Links

Same Category (Injectable Testosterone Medications)

• Testosterone Cypionate (Depo-Testosterone) — Most widely used injectable TRT formulation; closely related ester (cypionate vs enanthate)
• Testosterone Enanthate (Delatestryl) — Same active compound as Xyosted; intramuscular delivery via standard syringe
• Testosterone Undecanoate Injectable (Aveed / Nebido) — Long-acting injectable (every 10-14 weeks); REMS program required for Aveed
• Testosterone Propionate — Short-acting ester; faster onset and clearance
• Testosterone Cypionate Auto-Injector (Azmiro) — Another autoinjector option; contains cypionate instead of enanthate, IM not SubQ
• Sustanon 250 — Blend of four testosterone esters; primarily available outside the US

Related Treatment Options

• Testosterone Gels & Topicals Guide — Transdermal alternatives to injection
• Testosterone Injections Guide — Comprehensive overview of all injectable options
• TRT for Beginners — Starting guide for those new to testosterone replacement

Ancillary Medications

• HCG — Fertility preservation during TRT
• Enclomiphene — SERM alternative to exogenous testosterone
• Anastrozole (Arimidex) — Aromatase inhibitor for estrogen management
• Clomiphene Citrate (Clomid) — SERM for testosterone support and post-TRT recovery

Complementary Approaches

• Zinc — Supports testosterone production
• Vitamin D — Associated with testosterone levels
• Ashwagandha — Adaptogen with modest testosterone-supporting evidence